Metraipolis › archive › dc_2be0811dcfe7

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study — Europe PMC PMID:41980929

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41980929
DOI
10.1038/s41408-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-10-15T17:19:07.470Z
SHA-256 of the archived text
e68b64a69e6abe26277b75ec9af0b81524bb2531cbf79543d1707fabd105b606
Stable URL of this page
https://metraipolis.com/documento/dc_2be0811dcfe7

How to cite

Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study — Europe PMC PMID:41980929 — Europe PMC (en), https://europepmc.org/article/MED/41980929 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_2be0811dcfe7 (Metraipolis archive dc_2be0811dcfe7, sha256 e68b64a69e6abe26277b75ec9af0b81524bb2531cbf79543d1707fabd105b606)
BibTeX
@misc{dc2be0811dcfe7,
  title = {Safety and efficacy of ciltacabtagene autoleucel for relapsed/refractory multiple myeloma: a CIBMTR study — Europe PMC PMID:41980929},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41980929},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_2be0811dcfe7; sha256 e68b64a69e6abe26277b75ec9af0b81524bb2531cbf79543d1707fabd105b606},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41980929. Agents can read the archived copy with the MCP tool read_document.